UNASSIGNED: Sixty-two patients were randomly assigned to dezocine group (DS) and control group (MS). After spinal anesthesia, mask oxygen (5 L/min) and dexmedetomidine (0.1 ug/kg) were given. Five minutes later, patients in the DS group received an Intravenous (IV) bolus of sufentanil and 0.05mg/kg dezocine, while patients in the MS group only received an IV bolus of sufentanil.
UNASSIGNED: ED50 of DS group was 0.342 ug/kg, 95% confidence interval (CI) was (0.269, 0.623) ug/kg, and the ED50 of MS group was 0.291 ug/kg, 95% CI was (0.257, 0.346) ug/kg. There was no difference in the type and treatment measures of RD and hemodynamic changes between the two groups, and no serious adverse reactions occurred in either group.
UNASSIGNED: Dezocine can improve RD induced by sufentanil in patients with spinal anesthesia combined with low-dose dexmedetomidine, and increase the safety window of sufentanil use.
■62例患者随机分为地佐辛组(DS)和对照组(MS)。脊髓麻醉后,给予面罩氧气(5L/min)和右美托咪定(0.1ug/kg).五分钟后,DS组患者接受舒芬太尼和0.05mg/kg地佐辛的静脉(IV)推注,而MS组患者仅接受舒芬太尼静脉推注。
■DS组的ED50为0.342ug/kg,95%置信区间(CI)为(0.269,0.623)ug/kg,MS组的ED50为0.291ug/kg,95%CI为(0.257,0.346)ug/kg。两组在RD类型和治疗措施及血流动力学改变方面无差异,两组均未出现严重不良反应。
■地佐辛能改善舒芬太尼复合小剂量右美托咪定腰麻患者的RD,增加舒芬太尼使用的安全窗口。